A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat
about
FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic RetinopathyPrecursor-Directed Combinatorial Biosynthesis of Cinnamoyl, Dihydrocinnamoyl, and Benzoyl Anthranilates in Saccharomyces cerevisiaeFluorofenidone offers improved renoprotection at early interventions during the course of diabetic nephropathy in db/db mice via multiple pathwaysTherapeutic targets for treating fibrotic kidney diseasesRoot of Polygonum cuspidatum extract reduces progression of diabetes-induced mesangial cell dysfunction via inhibition of platelet-derived growth factor-BB (PDGF-BB) and interaction with its receptor in streptozotocin-induced diabetic rats.Sodium-Glucose Linked Cotransporter-2 Inhibition Does Not Attenuate Disease Progression in the Rat Remnant Kidney Model of Chronic Kidney Disease.Production of hydroxycinnamoyl anthranilates from glucose in Escherichia coliRenal disease pathophysiology and treatment: contributions from the rat.The endothelium in diabetic nephropathy.Novel targets of antifibrotic and anti-inflammatory treatment in CKD.New renal drug development to face chronic renal disease.Diagnosis and treatment of early renal disease in patients with type 2 diabetes mellitus: what are the clinical needs?The next generation of therapeutics for chronic kidney diseaseIncreased angiotensinogen expression, urinary angiotensinogen excretion, and tissue injury in nonclipped kidneys of two-kidney, one-clip hypertensive rats.N-Acetylcysteine Attenuates the Development of Renal Fibrosis in Transgenic Mice with Dilated Cardiomyopathy.
P2860
Q28546854-042588ED-6300-486F-B368-EC396DA3C370Q28548700-0EFA297C-6842-4E16-96D2-AF33AC0B9811Q34408514-F82015A5-5092-4439-BEC7-146A9E8F6175Q35079607-6C801A89-3055-4D0B-BC2E-BE7AFECCA9A9Q35191172-2AD5EF6D-4357-461C-894A-FC410F25F8CBQ35887931-0EAFF4DA-0A27-4A10-BA10-3BF43F798D84Q37028313-5415A45E-05AC-4331-B38E-AAA739D3DB14Q37545416-BD86F751-0771-48A8-9DD0-614BB237EF6EQ38195528-F546790C-97DE-4309-A6AC-AB2C3E980450Q38198872-134D0ABD-4A3C-4B9A-ADE7-59C49D169B88Q38246640-58E5F619-33EF-4AF1-A0DC-832275237D77Q38553908-DA3D4312-26C0-4404-89DB-4A5D6DDC4FEDQ38845590-6E01CF27-A8C3-4490-BADA-FE42F7A92E47Q40998872-2F5150D7-05E2-4B82-9123-77ED286AA4A4Q47156134-B00D942B-2C64-43FB-A33F-DA416180EB07
P2860
A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat
description
2012 nî lūn-bûn
@nan
2012 թուականին հրատարակուած գիտական յօդուած
@hyw
2012 թվականին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
name
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@ast
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@en
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@nl
type
label
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@ast
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@en
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@nl
prefLabel
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@ast
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@en
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@nl
P2093
P2860
P1433
P1476
A purpose-synthesised anti-fib ...... tal kidney diseases in the rat
@en
P2093
Alison J Cox
Darren J Kelly
David I Stapleton
Richard E Gilbert
Robyn Langham
Steven C Zammit
Yuan Zhang
P2860
P304
P356
10.1371/JOURNAL.PONE.0047160
P407
P577
2012-01-01T00:00:00Z